Program
guselkumab
Also written as “Guselkumab”, “Guselkumab Dose 1” and “Guselkumab Dose 2”.
Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 5818 open or running | phase 4since Jun 3, 2021 | Sep 2, 2011 | Feb 10, 2027phase 3 · NCT06260163 |
| Eli Lilly | 10 open or running | phase 4since Jun 20, 2018 | Jun 20, 2018 | none ahead |
| Surmount Services | 11 open or running | phase 1since Aug 20, 2026 | Aug 20, 2026 | Nov 20, 2026phase 1 · NCT07788807 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 2, 2011.
- Mar 1, 2022Phase 3 study in Plaque PsoriasisJohnson & Johnson · NCT05272150 · 211 enrolled · United States, Canada
- Apr 21, 2022Phase 3 study in Fistulizing Crohns DiseaseJohnson & Johnson · NCT05347095 · 288 enrolled · United States, Australia, Belgium and more
- Aug 19, 2022Phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT05528510 · 418 enrolled · United States, Argentina, Australia and more
- Mar 13, 2023Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT05784129 · 4 enrolled · United States, Poland
- Jun 20, 2023Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT05923073 · 120 planned · United States, Australia, Austria and more
- Sep 9, 2023Phase 3 study in Moderate Plaque PsoriasisJohnson & Johnson · NCT06039189 · 338 enrolled · United States, Canada
- Feb 7, 2024Phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT06260163 · 112 enrolled · United States, Australia, Belgium and more
- May 7, 2024Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT06408935 · 120 enrolled · United States, Australia, Belgium and more
- Oct 28, 2024Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT06663332 · 196 planned · United States, Argentina, Australia and more
- Aug 21, 2025Phase 4 study in Arthritis, PsoriaticJohnson & Johnson · NCT07141004 · 100 planned · India
- Dec 16, 2025Phase 4 study in Crohn DiseaseJohnson & Johnson · NCT07310095 · 78 planned · China
- Mar 23, 2026Phase 3 study in Crohn DiseaseJohnson & Johnson · NCT07499232 · 530 planned · United States, Austria, Belgium and more
- Jun 12, 2026Phase 4 study in PsoriasisJohnson & Johnson · NCT07654751 · 10 planned · United States
- Aug 20, 2026Surmount Services's first study: phase 1 study in Healthy SubjectsNew to Surmount ServicesSurmount Services · NCT07788807 · 18 planned · Australia
Ahead
- Nov 20, 2026Primary completion: phase 1 study in Healthy SubjectsSurmount Services · NCT07788807
- Feb 10, 2027Primary completion: phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT06260163
- Mar 25, 2027Primary completion: phase 3 study in Fistulizing Crohns DiseaseJohnson & Johnson · NCT05347095
- Apr 1, 2027Primary completion: phase 4 study in Arthritis, PsoriaticJohnson & Johnson · NCT04929210
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
Studies
All 60 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07788807Healthy Subjects · Australia | 1 | Recruiting | Surmount Services | Nov 20, 2026 | 18 |
| NCT07654751Psoriasis · United States | 4 | Recruiting | Johnson & Johnson | Aug 31, 2027 | 10 |
| NCT07499232Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Johnson & Johnson | Nov 15, 2028 | 530 |
| NCT07310095Crohn Disease · China | 4 | Recruiting | Johnson & Johnson | Sep 15, 2027 | 78 |
| NCT07141004Arthritis, Psoriatic · India | 4 | Recruiting | Johnson & Johnson | Jun 5, 2027 | 100 |
| NCT06663332Crohn Disease · United States, Argentina, Australia and more | 3 | Recruiting | Johnson & Johnson | Dec 12, 2031 | 196 |
| NCT06408935Crohn Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Jun 8, 2027 | 120 |
| NCT06260163Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 10, 2027 | 112 |
| NCT06039189Moderate Plaque Psoriasis · United States, Canada | 3 | Completed | Johnson & Johnson | Apr 14, 2025 | 338 |
| NCT05923073Crohn Disease · United States, Australia, Austria and more | 3 | Recruiting | Johnson & Johnson | Oct 27, 2027 | 120 |
| NCT05784129Crohn Disease · United States, Poland | 3 | Terminated | Johnson & Johnson | Sep 29, 2023 | 4 |
| NCT05528510Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Apr 2, 2024 | 418 |
| NCT05347095Fistulizing Crohns Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Mar 25, 2027 | 288 |
| NCT05272150Plaque Psoriasis · United States, Canada | 3 | Completed | Johnson & Johnson | May 30, 2025 | 211 |
| NCT05242484Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Active, not recruiting | Johnson & Johnson | May 15, 2025 | 577 |
| NCT05242471Crohn Disease · United States, Australia, Austria and more | 2 | Active, not recruiting | Johnson & Johnson | May 23, 2025 | 703 |
| NCT05197049Crohn Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Jul 4, 2023 | 350 |
| NCT05125679Psoriasis · Germany, Greece, Italy | 4 | Terminated | Johnson & Johnson | Jul 28, 2023 | 15 |
| NCT05083078Arthritis, Psoriatic · Austria | 1 | Terminated | Johnson & Johnson | Jul 1, 2022 | 11 |
| NCT05083182Arthritis, Juvenile · United States, Argentina, Denmark and more | 3 | Completed | Johnson & Johnson | Jan 12, 2026 | 48 |
| NCT04936308Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Oct 28, 2024 | 453 |
| NCT04929210Arthritis, Psoriatic · United States, Argentina, Australia and more | 4 | Active, not recruiting | Johnson & Johnson | Apr 1, 2027 | 411 |
| NCT04914429Psoriasis · China | 4 | Completed | Johnson & Johnson | Sep 26, 2023 | 327 |
| NCT04882098Arthritis, Psoriatic · United States, Australia, Bosnia and Herzegovina and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 30, 2024 | 1,054 |
| NCT04704843Celiac Disease · United States | 1 | Withdrawn | Johnson & Johnson | Sep 13, 2021 | 0 |
| NCT04683029Scleroderma, Systemic · Japan | 2 | Completed | Johnson & Johnson | May 17, 2023 | 56 |
| NCT04633447Giant Cell Arteritis · United States, Belgium, Canada and more | 2 | Terminated | Johnson & Johnson | May 22, 2024 | 53 |
| NCT04617691Healthy · Germany | 1 | Completed | Johnson & Johnson | Jul 20, 2021 | 140 |
| NCT04397263Crohn Disease · Japan | 3 | Completed | Johnson & Johnson | Feb 29, 2024 | 38 |
| NCT04376827Lupus Nephritis · United States, Argentina, Mexico and more | 2 | Terminated | Johnson & Johnson | Feb 1, 2023 | 33 |
| NCT04147338Healthy · United States, Germany | 1 | Completed | Johnson & Johnson | Sep 13, 2021 | 440 |
| NCT04033445Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Sep 19, 2023 | 1,064 |
| NCT04030533Healthy · China | 1 | Completed | Johnson & Johnson | Dec 31, 2020 | 60 |
| NCT03998683Psoriasis · France, Germany, Italy and more | 3 | Completed | Johnson & Johnson | Mar 2, 2021 | 117 |
| NCT03818035Psoriasis · France, Germany | 3 | Completed | Johnson & Johnson | Mar 7, 2022 | 880 |
| NCT03796858Arthritis, Psoriatic · Belgium, Bulgaria, France and more | 3 | Completed | Johnson & Johnson | Nov 11, 2020 | 285 |
| NCT03662542Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Dec 1, 2020 | 214 |
| NCT03649971Adenomatous Polyposis Coli · United States, France, Germany and more | 1 | Completed | Johnson & Johnson | Sep 13, 2021 | 77 |
| NCT03628924Hidradenitis Suppurativa · United States, Canada, Denmark and more | 2 | Completed | Johnson & Johnson | May 22, 2020 | 184 |
| NCT03573323Plaque Psoriasis · United States, Canada, Puerto Rico | 4 | Completed | Eli Lilly | Jul 15, 2019 | 1,027 |
| NCT03536325Healthy · Japan | 1 | Completed | Johnson & Johnson | Oct 25, 2018 | 24 |
| NCT03466411Crohn Disease · United States, Australia, Austria and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 20, 2023 | 1,409 |
| NCT03451851Psoriasis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | Jul 19, 2023 | 120 |
| NCT03162796Arthritis, Psoriatic · United States, Australia, Canada and more | 3 | Completed | Johnson & Johnson | Mar 14, 2019 | 383 |
| NCT03158285Arthritis, Psoriatic · United States, Bulgaria, Czechia and more | 3 | Completed | Johnson & Johnson | Feb 25, 2019 | 741 |
| NCT03090100Psoriasis · United States, Australia, Canada and more | 3 | Completed | Johnson & Johnson | Aug 2, 2018 | 1,048 |
| NCT02951533Psoriasis · Germany | 3 | Completed | Johnson & Johnson | Sep 13, 2017 | 119 |
| NCT02905331Psoriasis · United States, Canada, Poland | 3 | Completed | Johnson & Johnson | Feb 6, 2018 | 78 |
| NCT02641730Psoriasis · Japan | 3 | Completed | Johnson & Johnson | Mar 28, 2017 | 159 |
| NCT02570373Healthy · United States | 1 | Completed | Johnson & Johnson | Jan 12, 2016 | 8 |
| NCT02397382Psoriasis · United States | 1 | Completed | Johnson & Johnson | Aug 31, 2016 | 16 |
| NCT02343744Psoriasis · Japan | 3 | Completed | Johnson & Johnson | Dec 4, 2015 | 21 |
| NCT02325219Psoriasis · Japan | 3 | Completed | Johnson & Johnson | Mar 2, 2016 | 192 |
| NCT02319759Arthritis, Psoriatic · United States, Canada, Germany and more | 2 | Completed | Johnson & Johnson | May 31, 2016 | 149 |
| NCT02203032Psoriasis · United States, Australia, Canada and more | 3 | Completed | Johnson & Johnson | Dec 25, 2015 | 872 |
| NCT01866007Healthy · United States | 1 | Completed | Johnson & Johnson | Sep 20, 2013 | 141 |
| NCT01845987Psoriasis · Japan | 2 | Completed | Johnson & Johnson | Sep 2014 | 49 |
| NCT01645280Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more | 2 | Completed | Johnson & Johnson | Dec 2013 | 274 |
| NCT01483599Psoriasis · United States, Belgium, Canada and more | 2 | Completed | Johnson & Johnson | Nov 27, 2012 | 293 |
| NCT01484587Psoriasis · Japan | 1 | Completed | Johnson & Johnson | Apr 11, 2013 | 24 |
How it is read
Names in the registry
- “Guselkumab”, 43 entries
- “Guselkumab Dose 1”, 7 entries
- “Guselkumab Dose 2”, 7 entries
- “Guselkumab Dose 3”, 4 entries
- “Guselkumab 100 mg”, 2 entries
Conditions, from the studies’ own filings
- Psoriasis, 19 studies
- Crohn Disease, 11 studies
- Arthritis, Psoriatic, 10 studies
- Colitis, Ulcerative, 5 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.